Chronologische Übersicht der Veröffentlichungen der Biofrontera AG zur Forschungskooperation mit Maruho (Stand: )

Transkript

1 Chronologische Übersicht der Veröffentlichungen der Biofrontera AG zur Forschungskooperation mit Maruho (Stand: ) Hinweis: Hervorhebungen in Gelb sind nicht Teil der ursprünglichen Veröffentlichungen Ad-hoc-Meldung vom

2 Halbjahresbericht zum , Seite 19 (veröffentlicht am ) hte/2016/halbjahresfinanzbericht% _final_webpage.pdf Quartalsbericht zum , Seite 13 (veröffentlicht am ) hte/2016/quartalsmitteilung%20q3%202016_de_final.pdf Geschäftsbericht zum , Seite 13 (veröffentlicht am ) hte/2016/gb_de_2016.pdf

3 Geschäftsbericht zum , Seite (veröffentlicht am ) hte/2016/gb_de_2016.pdf Geschäftsbericht zum , Seite 56 (veröffentlicht am ) hte/2016/gb_de_2016.pdf Geschäftsbericht zum , Seite 84 (veröffentlicht am ) hte/2016/gb_de_2016.pdf

4 Stellungnahme des Vorstands der Biofrontera AG zur den Gegenanträgen der Deutsche Balaton AG vom Stellungnahme%20Gegenantraege.pdf Quartalsmitteilung zum , Seite 2 (veröffentlicht am ) hte/2017/quartalsmitteilung%20q1%202017_de_final.pdf

5 HV-Präsentation vom , Seite Halbjahresbericht zu , Seite 15 (veröffentlicht am ) hte/2017/biofrontera_halbjahresbericht_2017.pdf

6 Halbjahresbericht zum , Seite 16 (veröffentlicht am ) hte/2017/biofrontera_halbjahresbericht_2017.pdf Halbjahresbericht zum , Seite (veröffentlicht am ) hte/2017/biofrontera_halbjahresbericht_2017.pdf Halbjahresbericht zum , Seite 30 (veröffentlicht am ) hte/2017/biofrontera_halbjahresbericht_2017.pdf Interview ( Was erwarten sie hinsichtlich der Kooperation mit ihrem Aktionär Maruho? Lübbert: Diese Kooperation kann Biofrontera auf eine neue Stufe der Unternehmensentwicklung heben. Letztlich geht es darum, aus der heutigen One-Product-Company einen echten Player in der Dermatologie zu machen. Durch die Kooperation mit Maruho kann dies ohne den Einsatz eigener Liquidität gelingen. Aufgrund des laufenden Austauschs mit Maruho gehen wir auch davon aus, dass Maruho langfristig ein wesentlicher Shareholder bleiben will, um die operative Zusammenarbeit zu unterstreichen.

7 SEC Prospekt-Entwurf vom , Seite 61 We also generate revenue from development projects entered into with Maruho. Under a collaboration and partnership agreement we entered into with Maruho, development work for the product candidates will be carried out either by our personnel or by subcontractors that we select. All costs under these projects will be borne by Maruho (subject to a cap of 2.3 million) and invoiced from us to Maruho on a monthly basis. We generated revenue of 1.2 million from this agreement in the fiscal year ended December 31, SEC Prospekt-Entwurf vom , Seite 79 In July 2016, we entered into a collaboration and partnership agreement with Maruho, a pharmaceutical company based in Japan specializing in dermatology that is also an affiliate of Maruho Deutschland GmbH, a major shareholder of our company. This agreement provides for the joint development of up to four branded generic pharmaceutical product candidates using our proprietary formulation technology. SEC Prospekt-Entwurf vom , Seite 92 Our Development Collaboration with Maruho In July 2016, we entered into a collaboration and partnership agreement with Maruho, a pharmaceutical company based in Japan specializing in dermatology that is also an affiliate of Maruho Deutschland GmbH, a major shareholder of our company. This agreement provides for the joint development of up to four branded generic pharmaceutical product candidates for the European market using our proprietary formulation technology. The current agreement covers the initial part of the collaboration, in which the feasibility of the product development is tested, which we expect to be completed by the end of Under this agreement, Maruho will bear all the costs connected with the development of these pharmaceutical product candidates (subject to a cap of 2.3 million). If these product candidates progress to clinical development, the collaboration and partnership agreement provides that we will negotiate in good faith a new agreement with Maruho, without any obligation to enter into it. Maruho has not been granted any rights to our formulation technology in the first phase of the project. The collaboration and partnership agreement provides that, if the parties ultimately determine to enter into a new agreement, Biofrontera would be granted an exclusive sublicensable right to market the product in Europe. As the agreement is related to Europe only, there are currently no firm understandings with respect to other geographical regions. The collaboration and partnership agreement further specifies that all results, information and data developed during the term of such agreement will be the property of Maruho. Any intellectual property (such as trade secrets, copyrights, patents and other patent rights, trademarks and moral rights) developed during the term of such agreement will be the joint property of us and Maruho. We do not currently expect any such intellectual property to be developed during the term of the agreement. The collaboration and partnership agreement prohibits us from manufacturing, selling or otherwise dealing in any products similar to and competitive with the product candidates developed under the agreement without Maruho's consent. Maruho has the right to terminate the collaboration and partnership agreement for any or no reason. We believe that these development projects will not yield any products for commercial launch before

8 SEC Prospekt-Entwurf vom , Seite F36-F Related party disclosures In July 2016, Biofrontera AG entered into a collaboration and partnership agreement with Maruho Co., Ltd., a pharmaceutical company based in Japan specializing in dermatology that is also an affiliate of Maruho Deutschland GmbH, a major shareholder of Biofrontera AG. This agreement provides for the joint development of up to four branded generic pharmaceutical product candidates for the European market using Biofrontera AG s proprietary formulation technology. The current agreement covers the initial part of the collaboration, in which the feasibility of the product development is tested, which Biofrontera AG expects to be completed by the end of Under this agreement, Maruho will bear all the costs connected with the development of these pharmaceutical product candidates (subject to a cap of 2.3 million). If these product candidates progress to clinical development, the collaboration and partnership agreement provides that Biofrontera AG will negotiate in good faith a new agreement with Maruho, without any obligation to enter into it. Maruho has not been granted any rights to Biofrontera AG s formulation technology in the first phase of the project. The collaboration and partnership agreement provides that, if the parties ultimately determine to enter into a new agreement, Biofrontera AG would be granted an exclusive sublicensable right to market the product in Europe. As the agreement is related to Europe only, there are currently no firm understandings with respect to other geographical regions. The collaboration and partnership agreement further specifies that all results, information and data developed during the term of such agreement will be the property of Maruho. Any intellectual property (such as trade secrets, copyrights, patents and other patent rights, trademarks and moral rights) developed during the term of such agreement will be the joint property of Biofrontera AG and Maruho. We do not currently expect any such intellectual property to be developed during the term of the agreement. The collaboration and partnership agreement prohibits Biofrontera AG from manufacturing, selling or otherwise dealing in any products similar to and competitive with the product candidates developed under the agreement without Maruho's consent. Maruho has the right to terminate the collaboration and partnership agreement for any or no reason. This development partnership generated revenue of EUR 1.2 million in the financial year under review (previous year: EUR 0 thousand). Receivables due from Maruho amounted to EUR 0.5 million as of 31 December 2016 (31 December 2015: 0). Quartalsmitteilung zum , Seite 2 (veröffentlicht am ) hte/2017/biofrontera_quartalsmitteilungq32017_de.pdf

9 Wertpapierprospekt vom , Seite Wertpapierprospekt vom , Seite Finaler SEC-Prospekt vom , Seite 78 %20Final%20Prospectus%20dated%20February%2013,% pdf

10 Finaler SEC-Prospekt vom , Seite %20Final%20Prospectus%20dated%20February%2013,% pdf